SCHEMBL16853017

SCHEMBL16853017

Cc1c(C(O)CN2CCc3nc(-c4ccc(C#N)cn4)ncc3C2)ccc2c1COC2=O

nearest known ligand 0.79

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KCNJ1 P48048 20/20 0.79
▸ KCNH2 Q12809 5/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18156857 0.93 KCNJ1 (0.70) KCNJ1KCNH2
SCHEMBL16853015 0.90 KCNJ1 (0.86) KCNJ1KCNH2
SCHEMBL16853075 0.88 KCNJ1 (1.00) KCNJ1KCNH2
SCHEMBL31098406 0.84 KCNJ1 (0.80) KCNJ1KCNH2
SCHEMBL16853058 0.84 KCNJ1 (0.80) KCNJ1KCNH2
SCHEMBL18156853 0.84 KCNJ1 (0.74) KCNJ1KCNH2
SCHEMBL31098389 0.83 KCNJ1 (1.00) KCNJ1KCNH2
SCHEMBL16853059 0.83 KCNJ1 (1.00) KCNJ1KCNH2
SCHEMBL19475842 0.83 KCNJ1 (1.00) KCNJ1KCNH2
SCHEMBL30569173 0.83 KCNJ1 (1.00) KCNJ1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3083573-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC (US) 2024-08-07 — — EP disclosed
US-10000484-B2 Inhibitors of the renal outer medullary potassim channel MERCK SHARP & DOHME CORP. (US) 2018-06-19 — — US disclosed
US-10000484-B2 Inhibitors of the renal outer medullary potassim channel MERCK SHARP & DOHME CORP. (US) 2018-06-19 — — US disclosed
US-10000484-B2 Inhibitors of the renal outer medullary potassim channel MERCK SHARP & DOHME CORP. (US) 2018-06-19 — — US disclosed
US-20160304515-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL MERCK SHARP & DOHME LLC 2016-10-20 — — US disclosed
US-20160304515-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL MERCK SHARP & DOHME LLC 2016-10-20 — — US disclosed
US-20160304515-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL MERCK SHARP & DOHME LLC 2016-10-20 — — US disclosed
WO-2015095097-A2 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2015-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000484-B2 Inhibitors of the renal outer medullary potassim channel KCNJ11, KCNJ1, KCNJ2 KCNJ1 2/4885KCNH2 32/4885
US-20160304515-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIM CHANNEL KCNJ11, KCNJ1, KCNJ2 KCNJ1 2/4885KCNH2 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback